Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAPN1 | P07384 | 1/20 | 0.34 |
| ▸ | HTR1D | P28221 | 1/20 | 0.34 |
| ▸ | HTR1B | P28222 | 1/20 | 0.34 |
| ▸ | CTSL | P07711 | 2/20 | 0.32 |
| ▸ | KLK7 | P49862 | 1/20 | 0.31 |
| ▸ | TACR1 | P25103 | 2/20 | 0.31 |
| ▸ | HTR1A | P08908 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 3/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | P4HB | P07237 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | CTSS | P25774 | 1/20 | 0.30 |
| ▸ | CTSK | P43235 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3770009 | 0.83 | HTR1D (0.36) | HTR1DHTR1BHTR1ASLC6A4MAPT | |
| SCHEMBL4533872 | 0.83 | HTR1D (0.31) | HTR1DHTR1B | |
| SCHEMBL8251805 | 0.82 | REN (0.35) | — | |
| SCHEMBL4756438 | 0.79 | PDE2A (0.32) | CTSK | |
| SCHEMBL4756776 | 0.79 | PDE2A (0.32) | CTSK | |
| SCHEMBL4756446 | 0.79 | PDE2A (0.32) | CTSK | |
| SCHEMBL9907055 | 0.76 | REN (0.35) | — | |
| SCHEMBL9907042 | 0.76 | REN (0.35) | — | |
| SCHEMBL9907061 | 0.76 | REN (0.34) | — | |
| SCHEMBL4754048 | 0.74 | BRD4 (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7851634-B2 | 5-amino 4-hydroxy-7-(1H-indolmethyl)-8-methylnonamide derivatives as renin inhibitors for the treatment of hypertension | NOVARTIS AG (CH) | 2010-12-14 | — | — | US | disclosed |
| EP-1717226-B1 | 2,7-SUBSTITUTED 5-AMINO-4-HYDROXY-8-(1H-INDOL-5-YL)-OCTAN AMIDE DERIVATIVES AS RENIN INHIBITORS FOR THE TREATMENT OF HYPERTENSION | SPEEDEL EXPERIMENTA AG (CH) | 2009-01-21 | — | — | EP | disclosed |
| US-20080280895-A1 | 5-Amino-4-Hydroxy-7-(1H-Indolmethyl)-8-Methylnonamide Derivatives as Renin Inhibitors for the Treatment of Hypertension | NOVARTIS AG (CH) | 2008-11-13 | — | — | US | disclosed |
| EP-1724259-A1 | 2,7-SUBSTITUTED 5-AMINO-4-HYDROXY-8-(1H-INDAZOL-5-YL)-OCTAN AMIDE DERIVATIVES AND RELATED COMPOUNDS AS RENIN INHIBITORS FOR THE TREATMENT OF HYPERTENSION | Speedel Experimenta AG (CH) | 2006-11-22 | — | — | EP | disclosed |
| EP-1717226-A1 | 2,7-SUBSTITUTED 5-AMINO-4-HYDROXY-8-(1H-INDOL-5-YL)-OCTAN AMIDE DERIVATIVES AS RENIN INHIBITORS FOR THE TREATMENT OF HYPERTENSION | Speedel Experimenta AG (CH) | 2006-11-02 | — | — | EP | disclosed |
| EP-1712548-A2 | 5-AMINO-4-HYDROXY-7-(PYRIDINYLMETHYL)-ALKANAMIDE DERIVATIVES AND RELATED COMPOUNDS AS RENIN INHIBITORS FOR THE TREATMENT OF HYPERTENSION | Speedel Experimenta AG (CH) | 2006-10-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280895-A1 | 5-Amino-4-Hydroxy-7-(1H-Indolmethyl)-8-Methylnonamide Derivatives as Renin Inhibitors for the Treatment of Hypertension | REN, AGTR1, AGTR2 | CAPN1 429/4885HTR1D 197/4885HTR1B 213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.